Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Cipla, with Plants in China and India, Goes After Biosimilar Market

publication date: Sep 21, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Cipla, the Indian generic drugmaker, revealed it has invested $165 million to build facilities in China and India to produce biosimilars. The company is working on developing copies of at least a dozen biotech drugs with a goal of charging only one-third their current price. Last year, Cipla paid $25 million to buy a 25% stake in BioMab, a Shanghai maker of biotech drugs. Cipla and BioMab both contributed to the $165 million investment, though details were not disclosed. More details....

Stock Symbol: (BSE: 500087)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...